22 results on '"Worst, Thomas S."'
Search Results
2. Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort
- Author
-
Neuberger, Manuel, Goly, Nora, Skladny, Janina, Milczynski, Veronica, Weiß, Christel, Wessels, Frederik, Nitschke, Katja, Grüne, Britta, Haney, Caelán M., Hartung, Friedrich, Herrmann, Jonas, Jarczyk, Jonas, Kowalewski, Karl F., Waldbillig, Frank, Kriegmair, Maximilian C., Westhoff, Niklas, Worst, Thomas S., and Nuhn, Philipp
- Published
- 2023
- Full Text
- View/download PDF
3. Peritoneal Flap for Lymphocele Prophylaxis Following Robotic-assisted Radical Prostatectomy with Lymph Node Dissection: The Randomised Controlled Phase 3 PELYCAN Trial
- Author
-
Neuberger, Manuel, Kowalewski, Karl-Friedrich, Simon, Valentin, von Hardenberg, Jost, Siegel, Fabian, Wessels, Frederik, Worst, Thomas S., Michel, Maurice Stephan, Westhoff, Niklas, Kriegmair, Maximilian C., Honeck, Patrick, and Nuhn, Philipp
- Published
- 2024
- Full Text
- View/download PDF
4. Immuntherapien in der Uroonkologie: Ansprechen und Therapieunterbrechungen durch Nebenwirkungen in einer bizentrischen Real-world-Analyse
- Author
-
Burger, Ralph, Jarczyk, Jonas, Westhoff, Niklas, Worst, Thomas S., Herrmann, Jonas, Merx, Kirsten, Weidner, Anja, Unglaub, Petra, Müller, Markus, Nuhn, Philipp, Michel, Maurice Stephan, and von Hardenberg, Jost
- Published
- 2022
- Full Text
- View/download PDF
5. Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy
- Author
-
Neuberger, Manuel, Weiß, Christel, Goly, Nora, Skladny, Janina, Nitschke, Katja, Wessels, Frederik, Kowalewski, Karl F., Waldbillig, Frank, Hartung, Friedrich, Nientiedt, Malin, Egen, Luisa, Herrmann, Jonas, Jarczyk, Jonas, Walach, Margarete Teresa, Kriegmair, Maximilian C., Westhoff, Niklas, Worst, Thomas S., and Nuhn, Philipp
- Published
- 2022
- Full Text
- View/download PDF
6. Holmium Versus Thulium Laser Enucleation of the Prostate: A Systematic Review and Meta-analysis of Randomized Controlled Trials
- Author
-
Hartung, Friedrich O., Kowalewski, Karl-Friedrich, von Hardenberg, Jost, Worst, Thomas S., Kriegmair, Maximilian C., Nuhn, Philipp, Herrmann, Thomas R.W., Michel, Maurice S., and Herrmann, Jonas
- Published
- 2022
- Full Text
- View/download PDF
7. High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma
- Author
-
Breyer, Johannes, Wirtz, Ralph M., Erben, Philipp, Worst, Thomas S., Stoehr, Robert, Eckstein, Markus, Sikic, Danijel, Burger, Maximilian, Hartmann, Arndt, Otto, Wolfgang, Bertz, Simone, and Denzinger, Stefan
- Published
- 2018
- Full Text
- View/download PDF
8. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients
- Author
-
Breyer, Johannes, Wirtz, Ralph M., Otto, Wolfgang, Erben, Philipp, Worst, Thomas S., Stoehr, Robert, Eckstein, Markus, Denzinger, Stefan, Burger, Maximilian, and Hartmann, Arndt
- Published
- 2018
- Full Text
- View/download PDF
9. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making
- Author
-
Worst, Thomas S., Weis, Cleo-Aron, Stöhr, Robert, Bertz, Simone, Eckstein, Markus, Otto, Wolfgang, Breyer, Johannes, Hartmann, Arndt, Bolenz, Christian, Wirtz, Ralph M., and Erben, Philipp
- Published
- 2018
- Full Text
- View/download PDF
10. Discrepancy between German S3 Guideline Recommendations and Daily Urologic Practice in the Management of Nonmuscle Invasive Bladder Cancer: Results of a Binational Survey.
- Author
-
Struck, Julian P., Hennig, Martin J.P., Hupe, Marie C., Moharam, Nadim, Paffenholz, Pia, Nestler, Tim, Frank, Tanja, Worst, Thomas S., Grabbert, Markus, Pohlmann, Philippe-Fabian, Dogan, Serkan, Hofbauer, Sebastian L., Kalogirou, Charis, Mattigk, Angelika, Brandt, Maximilian P., Krabbe, Laura-Maria, Reis, Henning, Dressler, Franz F., Kramer, Mario W., and Salem, Johannes
- Subjects
NON-muscle invasive bladder cancer ,BLADDER cancer ,TRANSURETHRAL resection of bladder - Abstract
Introduction: Guideline recommendations are meant to help minimize morbidity and to improve the care of nonmuscle invasive bladder cancer (NMIBC) patients but studies have suggested an underuse of guideline-recommended care. The aim of this study was to evaluate the level of adherence of German and Austrian urologists to German guideline recommendations. Methods: A survey of 27 items evaluating diagnostic and therapeutic recommendations (15 cases of strong consensus and 6 cases of consensus) for NMIBC was administered among 14 urologic training courses. Survey construction and realization followed the checklist for reporting results of internet e-surveys and was approved by an internal review board. Results: Between January 2018 and June 2019, a total of 307 urologists responded to the questionnaire, with a mean response rate of 71%. The data showed a weak role of urine cytology (54%) for initial diagnostics although it is strongly recommended by the guideline. The most frequently used supporting diagnostic tool during transurethral resection of the bladder was hexaminolevulinate (95%). Contrary to the guideline recommendation, 38% of the participants performed a second resection in the case of pTa low-grade NMIBC. Correct monitoring of Bacille Calmette-Guérin (BCG) response with cystoscopy and cytology was performed by only 34% of the urologists. Conclusions: We found a discrepancy between certain guideline recommendations and daily routine practice concerning the use of urine cytology for initial diagnostics, instillation therapy with a low monitoring rate of BCG response, and follow-up care with unnecessary second resection after pTa low-grade NMIBC in particular. Our survey showed a moderate overall adherence rate of 73%. These results demonstrate the need for sharpening awareness of German guideline recommendations by promoting more intense education of urologists to optimize NMIBC care thus decreasing morbidity and mortality rates. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Artificial intelligence to predict oncological outcome directly from hematoxylin and eosin-stained slides in urology.
- Author
-
WESSELS, Frederik, KUNTZ, Sara, KRIEGHOFF-HENNING, Eva, SCHMITT, Max, BRAUN, Volker, WORST, Thomas S., NEUBERGER, Manuel, STEEG, Matthias, GAISER, Timo, FRÖHLING, Stefan, MICHEL, Maurice-Stephan, NUHN, Philipp, and BRINKER, Titus J.
- Published
- 2022
- Full Text
- View/download PDF
12. Deep learning can predict survival directly from histology in clear cell renal cell carcinoma.
- Author
-
Wessels, Frederik, Schmitt, Max, Krieghoff-Henning, Eva, Kather, Jakob N., Nientiedt, Malin, Kriegmair, Maximilian C., Worst, Thomas S., Neuberger, Manuel, Steeg, Matthias, Popovic, Zoran V., Gaiser, Timo, von Kalle, Christof, Utikal, Jochen S., Fröhling, Stefan, Michel, Maurice S., Nuhn, Philipp, and Brinker, Titus J.
- Subjects
RENAL cell carcinoma ,DEEP learning ,RECEIVER operating characteristic curves ,CONVOLUTIONAL neural networks - Abstract
For clear cell renal cell carcinoma (ccRCC) risk-dependent diagnostic and therapeutic algorithms are routinely implemented in clinical practice. Artificial intelligence-based image analysis has the potential to improve outcome prediction and thereby risk stratification. Thus, we investigated whether a convolutional neural network (CNN) can extract relevant image features from a representative hematoxylin and eosin-stained slide to predict 5-year overall survival (5y-OS) in ccRCC. The CNN was trained to predict 5y-OS in a binary manner using slides from TCGA and validated using an independent in-house cohort. Multivariable logistic regression was used to combine of the CNNs prediction and clinicopathological parameters. A mean balanced accuracy of 72.0% (standard deviation [SD] = 7.9%), sensitivity of 72.4% (SD = 10.6%), specificity of 71.7% (SD = 11.9%) and area under receiver operating characteristics curve (AUROC) of 0.75 (SD = 0.07) was achieved on the TCGA training set (n = 254 patients / WSIs) using 10-fold cross-validation. On the external validation cohort (n = 99 patients / WSIs), mean accuracy, sensitivity, specificity and AUROC were 65.5% (95%-confidence interval [CI]: 62.9–68.1%), 86.2% (95%-CI: 81.8–90.5%), 44.9% (95%-CI: 40.2–49.6%), and 0.70 (95%-CI: 0.69–0.71). A multivariable model including age, tumor stage and metastasis yielded an AUROC of 0.75 on the TCGA cohort. The inclusion of the CNN-based classification (Odds ratio = 4.86, 95%-CI: 2.70–8.75, p < 0.01) raised the AUROC to 0.81. On the validation cohort, both models showed an AUROC of 0.88. In univariable Cox regression, the CNN showed a hazard ratio of 3.69 (95%-CI: 2.60–5.23, p < 0.01) on TCGA and 2.13 (95%-CI: 0.92–4.94, p = 0.08) on external validation. The results demonstrate that the CNN's image-based prediction of survival is promising and thus this widely applicable technique should be further investigated with the aim of improving existing risk stratification in ccRCC. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Deep learning approach to predict lymph node metastasis directly from primary tumour histology in prostate cancer.
- Author
-
Wessels, Frederik, Schmitt, Max, Krieghoff‐Henning, Eva, Jutzi, Tanja, Worst, Thomas S., Waldbillig, Frank, Neuberger, Manuel, Maron, Roman C., Steeg, Matthias, Gaiser, Timo, Hekler, Achim, Utikal, Jochen S., von Kalle, Christof, Fröhling, Stefan, Michel, Maurice S., Nuhn, Philipp, and Brinker, Titus J.
- Subjects
LYMPHATIC metastasis ,DEEP learning ,GLEASON grading system ,PROSTATECTOMY ,HISTOLOGY ,RECEIVER operating characteristic curves ,CONVOLUTIONAL neural networks ,AGE factors in cancer ,SIGNAL convolution - Abstract
Objective: To develop a new digital biomarker based on the analysis of primary tumour tissue by a convolutional neural network (CNN) to predict lymph node metastasis (LNM) in a cohort matched for already established risk factors. Patients and Methods: Haematoxylin and eosin (H&E) stained primary tumour slides from 218 patients (102 N+; 116 N0), matched for Gleason score, tumour size, venous invasion, perineural invasion and age, who underwent radical prostatectomy were selected to train a CNN and evaluate its ability to predict LN status. Results: With 10 models trained with the same data, a mean area under the receiver operating characteristic curve (AUROC) of 0.68 (95% confidence interval [CI] 0.678–0.682) and a mean balanced accuracy of 61.37% (95% CI 60.05–62.69%) was achieved. The mean sensitivity and specificity was 53.09% (95% CI 49.77–56.41%) and 69.65% (95% CI 68.21–71.1%), respectively. These results were confirmed via cross‐validation. The probability score for LNM prediction was significantly higher on image sections from N+ samples (mean [SD] N+ probability score 0.58 [0.17] vs 0.47 [0.15] N0 probability score, P = 0.002). In multivariable analysis, the probability score of the CNN (odds ratio [OR] 1.04 per percentage probability, 95% CI 1.02–1.08; P = 0.04) and lymphovascular invasion (OR 11.73, 95% CI 3.96–35.7; P < 0.001) proved to be independent predictors for LNM. Conclusion: In our present study, CNN‐based image analyses showed promising results as a potential novel low‐cost method to extract relevant prognostic information directly from H&E histology to predict the LN status of patients with prostate cancer. Our ubiquitously available technique might contribute to an improved LN status prediction. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer.
- Author
-
Sikic, Danijel, Taubert, Helge, Breyer, Johannes, Eckstein, Markus, Weyerer, Veronika, Keck, Bastian, Kubon, Jennifer, Otto, Wolfgang, Worst, Thomas S, Kriegmair, Maximilian C, Erben, Philipp, Hartmann, Arndt, Wullich, Bernd, Wirtz, Ralph M, and Wach, Sven
- Subjects
CANCER invasiveness ,FIBROBLAST growth factor receptors ,URETHRA ,CYCLIN-dependent kinase inhibitors ,BLADDER cancer ,OVERALL survival ,UROTHELIUM - Abstract
Purpose: Fibroblast growth factor receptor 3 (FGFR3) alterations are frequent in non-muscle-invasive bladder cancer (NMIBC), although current data regarding the prognostic and therapeutic relevance are inconsistent. We analyzed the prognostic role of FGFR3 mRNA expression in stage T1 NMIBC. Patients and Methods: The mRNA expression of FGFR3 and cyclin-dependent kinase inhibitor 2A (CDKN2A) was measured by RT-qPCR in 80 patients with stage T1 NMIBC treated with transurethral resection of the bladder and correlated with clinical data and KRT5 and KRT20 expression, used as surrogate markers for basal and luminal subtypes, respectively. Results: FGFR3 and CDKN2A transcript levels were not correlated. FGFR3 expression was associated with the expression of KRT5 (p=0.002) and KRT20 (p < 0.001). CDKN2A expression was negatively correlated with KRT5 (p=0.030). In Kaplan–Meier analysis and univariable Cox regression analysis, high FGFR3 expression was associated with significantly reduced recurrence-free survival (RFS) (HR=3.78; p < 0.001) and improved overall survival (OS) (HR=0.50; p=0.043), while high CDKN2A expression was associated with reduced OS (HR=2.34; p=0.034). Patient age was the only clinicopathological parameter associated with reduced OS (HR=2.29; p=0.022). No parameter was an independent prognostic factor in multivariable analysis. Next, we stratified the patients depending on their lineage differentiation. In univariable analysis, the prognostic effect of FGFR3 and CDKN2A was observed primarily in patients demonstrating high expression of KRT5 or KRT20, whereas high FGFR3 expression was associated with significantly reduced RFS, irrespective of instillation therapy. Conclusion: Stage T1 NMIBC patients with high FGFR3 expression show shorter RFS but better OS than patients with low FGFR3 expression. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non‐muscle‐invasive bladder cancer.
- Author
-
Breyer, Johannes, Wirtz, Ralph M., Erben, Philipp, Rinaldetti, Sebastien, Worst, Thomas S., Stoehr, Robert, Eckstein, Markus, Sikic, Danijel, Denzinger, Stefan, Burger, Maximilian, Hartmann, Arndt, and Otto, Wolfgang
- Subjects
MICRORNA ,GENE expression ,TRANSITIONAL cell carcinoma ,CANCER chemotherapy ,CYSTECTOMY - Abstract
Objective: To investigate the role of forkhead box protein M1 (FOXM1) mRNA expression and its prognostic value in stage pT1 non‐muscle‐invasive bladder cancer (NMIBC). Patients and Methods: Clinical data and formalin‐fixed paraffin‐embedded tissues from transurethral resection of the bladder from patients with stage pT1 NMIBC, treated with an organ‐preserving approach, were analysed retrospectively. Total RNA was isolated using commercial RNA extraction kits, and mRNA expression of FOXM1, MKI67, KRT20 and KRT5 was measured by single‐step quantitative RT‐PCR using RNA‐specific TaqMan Assays. Statistical analysis was performed using Spearman's Rho, Wilcoxon or Kruskal–Wallis tests, Kaplan–Meier estimates of recurrence‐free (RFS), progression‐free (PFS) and cancer‐specific survival (CSS) and Cox regression analysis. Results: Data from 296 patients (79.4% men, median age 72 years) were available for the final evaluation. Spearman correlation analysis showed that mRNA expression of FOXM1 was significantly correlated with MKI67 (ρ: 0.6530, P < 0.001) and with the luminal subtype, reflected by the positive correlation with KRT20 (ρ: 0.2113, P < 0.001). Furthermore, there was also a strong correlation of FOXM1 expression with adverse clinical and pathological variables, such as concomitant carcinoma in situ (P = 0.05), multifocal tumours (P = 0.005) and World Health Organization 1973 grade 3 disease (P < 0.001). Kaplan–Meier analysis showed overexpression of FOMX1 to be associated with worse PFS (P = 0.028) and worse CSS (P = 0.015). FOXM1 overexpression was also shown to be a predictive risk factor for CSS (hazard ratio 1.61 [1.13–2.34], L‐R chi‐squared: 7.19, P = 0.007). FOXM1 overexpression identified a subgroup of patients within the luminal subtype with worse RFS (P = 0.017), PFS (P < 0.001) and CSS (P = 0.015). Patients with low FOXM1 expression had better outcomes, irrespective of instillation therapy, whereas patients with high FOXM1 expression benefitted from intravesical chemotherapy with mitomycin C. Conclusion: High FOXM1 expression was associated with adverse clinical and pathological features and worse outcomes, and predicted response to intravesical instillation therapy in patients with stage pT1 NMIBC. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate Cancer.
- Author
-
von Hardenberg, Jost, Worst, Thomas S., Westhoff, Niklas, Erben, Philipp, Fuxius, Stefan, Müller, Markus, Bolenz, Christian, Weiss, Christel, and Heinrich, Elmar
- Subjects
- *
PROSTATE cancer treatment , *CANCER cells , *ONCOLOGY , *CHROMOGRANINS , *DNA - Abstract
Background: Aggressive variant transformation in metastatic castration-resistant prostate cancer (mCRPC) represents an under-recognized phenomenon. There is an urgent need for non-invasive biomarkers to detect these variants and identify treatment alternatives. Methods: A prospective observational pilot study in mCRPC patients receiving treatment with cabazitaxel (CAB) was conducted. Neuromediators were sequentially evaluated and their impact on disease endpoints calculated. Targeted next-generation sequencing (NGS) of cell-free DNA (cfDNA) was also performed in a highly pretreated subset of patients. Results: 23 patients were included. Estimated effects indicate that neuron-specific enolase (NSE) levels at baseline may be correlated with overall survival (NSE unit 18.3 ng/ml: HR1.262 (95% confidence interval (CI) 0.985-1.616)) and that chromogranin A (CGA) may be correlated with progression-free survival (CGA unit 98.1 ng/ml: HR1.341 (95% CI 1.011-1.778)). cfDNA analysis revealed mutations annotated in prostate cancer (PCA) and small cell cancers (SCC). 1 patient showed elevated neuromediators along with annotated mutations in PCA and SCC, potentially indicating aggressive variant cancer. In 3 patients KIT mutations (e.g. pM541L, pV654A) known to be tissue-based biomarkers with level 1 evidence for the treatment with imatinib and sunitinib were found. Conclusions: Sequential analysis of neuromediators and targeted NGS of cfDNA provide insight for the estimation of tumor heterogeneity under therapy with CAB. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. IL1RN and KRT13 Expression in Bladder Cancer: Association with Pathologic Characteristics and Smoking Status.
- Author
-
Worst, Thomas S., Reiner, Verena, Gabriel, Ute, Weiß, Christel, Erben, Philipp, Martini, Thomas, and Bolenz, Christian
- Subjects
- *
BLADDER cancer , *SMOKING , *CYSTECTOMY , *TRANSITIONAL cell carcinoma , *IMMUNOSTAINING , *CYSTOTOMY - Abstract
Purpose. To validate microarray data on cytokeratin 13 (KRT13) and interleukin-1 receptor antagonist (IL1RN) expression in urothelial carcinoma of the urinary bladder (UCB) and to correlate our findings with pathologic characteristics and tobacco smoking. Methods. UCB tissue samples (n = 109) and control samples (n = 14) were obtained from transurethral resection and radical cystectomy specimens. Immunohistochemical staining of KRT13 and IL1RN was performed and semiquantitative expression scores were assessed. Smoking status was evaluated using a standardized questionnaire. Expression scores were correlated with pathologic characteristics (tumor stage and grade) and with smoking status. Results. Loss of KRT13 and IL1RN expression was observed in UCB tissue samples when compared to controls (P = 0.007, P = 0.008) in which KRT13 and IL1RN expression were high. IL1RN expression was significantly reduced in muscle-invasive tumors (P = 0.003). In tissue samples of current smokers, a significant downregulation of IL1RN was found when compared to never smokers (P = 0.013). Conclusion. Decreased expressions of KRT13 and IL1RN are common features of UCB and are associated with aggressive disease. Tobacco smoking may enhance the loss of IL1RN, indicating an overweight of proinflammatory mediators involved in UCB progression. Further validation of the influence of smoking on IL1RN expression is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
18. High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer.
- Author
-
Nitschke, Katja, Worst, Thomas S., von Rhade, Sophie Madeleine, Thaqi, Blerta, Neuberger, Manuel, Wessels, Frederik, Weis, Cleo-Aron, Porubsky, Stefan, Gaiser, Timo, Kriegmair, Maximilian, von Hardenberg, Jost, Weidenbusch, Marc, Erben, Philipp, and Nuhn, Philipp
- Subjects
- *
CANCER invasiveness , *GENE expression , *BIOMARKERS , *OVERALL survival , *EPITHELIUM , *BLADDER cancer , *CYSTECTOMY , *SURVIVAL , *CELL receptors , *PROGNOSIS , *MUSCLE tumors , *LONGITUDINAL method ,BLADDER tumors - Abstract
Background: The cell surface interleukin 22 (IL-22) receptor complex is mainly expressed in epithelial and tissue cells like pancreatitis cells. Recent studies described that IL-22R was overexpressed in malignant diseases and was associated with a poor overall survival (OS). The role of IL-22RA1 gene expression in muscle invasive bladder cancer (MIBC) has not been investigated, yet.Objectives: The aim of this study was to analyze the role of IL-22RA1 gene expression in patients with MIBC.Methods: In a cohort of 114 patients with MIBC who underwent radical cystectomy, IL-22RA1 gene expression was analyzed with qRT-PCR and correlated with clinical parameters. Furthermore, Kaplan-Meier and Cox regression analysis were performed. For validation, an in silico dataset (TCGA 2017, n=407) was reanalyzed.Results: IL-22RA1 gene expression was independent of clinicopathological parameters like age (P=0.2681), T stage (P=0.2130), nodal status (P=0.3238) and lymph vascular invasion (LVI, P=0.5860) in patients with MIBC. A high expression of IL-22RA1 was associated with a shorter OS (P=0.0040) and disease-specific survival (P=0.0385). Furthermore, a shorter disease-free survival (DFS) was also associated with a high expression of IL-22RA1 (P=0.0102). In the multivariable analysis, IL-22RA1 expression was an independent prognostic predictors regarding OS (P=0.0096, HR=0.48). In the TCGA cohort, IL-22RA1 expression was independent regarding to OS and DFS.Conclusion: A high IL-22RA1 gene expression was associated with worse outcome. Furthermore, IL-22RA1 represented an independent predictor regarding OS in our cohort and therefore might be used for risk stratification in patients with MIBC. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
19. The Impact of Small Extracellular Vesicles on Lymphoblast Trafficking across the Blood-Cerebrospinal Fluid Barrier In Vitro.
- Author
-
Erb, Ulrike, Hikel, Julia, Meyer, Svenja, Ishikawa, Hiroshi, Worst, Thomas S., Nitschke, Katja, Nuhn, Philipp, Porubsky, Stefan, Weiss, Christel, Schroten, Horst, Adam, Rüdiger, and Karremann, Michael
- Subjects
EXOSOMES ,BLOOD-brain barrier ,EXTRACELLULAR vesicles ,CHOROID plexus ,CENTRAL nervous system ,CEREBROSPINAL fluid examination ,LYMPHOBLASTIC leukemia - Abstract
Central nervous System (CNS) disease in pediatric acute lymphoblastic leukemia (ALL) is a major concern, but still, cellular mechanisms of CNS infiltration are elusive. The choroid plexus (CP) is a potential entry site, and, to some extent, invasion resembles CNS homing of lymphocytes during healthy state. Given exosomes may precondition target tissue, the present work aims to investigate if leukemia-derived exosomes contribute to a permissive phenotype of the blood-cerebrospinal fluid barrier (BCSFB). Leukemia-derived exosomes were isolated by ultracentrifugation from the cell lines SD-1, Nalm-6, and P12-Ichikawa (P12). Adhesion and uptake to CP epithelial cells and the significance on subsequent ALL transmigration across the barrier was studied in a human BCSFB in vitro model based on the HiBCPP cell line. The various cell lines markedly differed regarding exosome uptake to HiBCPP and biological significance. SD-1-derived exosomes associated to target cells unspecifically without detectable cellular effects. Whereas Nalm-6 and P12-derived exosomes incorporated by dynamin-dependent endocytosis, uptake in the latter could be diminished by integrin blocking. In addition, only P12-derived exosomes led to facilitated transmigration of the parental leukemia cells. In conclusion, we provide evidence that, to a varying extent, leukemia-derived exosomes may facilitate CNS invasion of ALL across the BCSFB without destruction of the barrier integrity. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy.
- Author
-
Sikic, Danijel, Eckstein, Markus, Wirtz, Ralph M., Jarczyk, Jonas, Worst, Thomas S., Porubsky, Stefan, Keck, Bastian, Kunath, Frank, Weyerer, Veronika, Breyer, Johannes, Otto, Wolfgang, Rinaldetti, Sebastien, Bolenz, Christian, Hartmann, Arndt, Wullich, Bernd, and Erben, Philipp
- Subjects
BLADDER cancer ,GENE expression ,CYSTECTOMY ,POLYMERASE chain reaction ,PROGRESSION-free survival - Abstract
It remains unclear how to implement the recently revealed basal and luminal subtypes of muscle-invasive bladder cancer (MIBC) into daily clinical routine and whether molecular marker panels can be reduced. The mRNA expression of basal (KRT5) and luminal (FOXA1, GATA3, KRT20) markers was measured by reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) and correlated to clinicopathological features, recurrence-free survival (RFS), disease-free survival (DFS), and overall survival (OS) in 80 patients with MIBC who underwent radical cystectomy. Additionally, the correlation of single markers with the basal and non-basal subtypes defined by a 36-gene panel was examined and then validated in the TCGA (The Cancer Genome Atlas) cohort. High expression of FOXA1 (p = 0.0048) and KRT20 (p = 0.0317) was associated with reduced RFS. In the multivariable analysis, only FOXA1 remained an independent prognostic marker for DFS (p = 0.0333) and RFS (p = 0.0310). FOXA1 expression (AUC = 0.79; p = 0.0007) was closest to the combined marker expression (AUC = 0.79; p = 0.0015) in resembling the non-basal subtype defined by the 36-gene panel. FOXA1 in combination with KRT5 may be used to distinguish the basal and non-basal subtypes of MIBC. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
- Author
-
Eckstein, Markus, Erben, Philipp, Kriegmair, Maximilian C., Worst, Thomas S., Weiß, Cleo-Aron, Wirtz, Ralph M., Wach, Sven, Stoehr, Robert, Sikic, Danijel, Geppert, Carol I., Weyerer, Veronika, Bertz, Simone, Breyer, Johannes, Otto, Wolfgang, Keck, Bastian, Burger, Maximilian, Taubert, Helge, Weichert, Wilko, Wullich, Bernd, and Bolenz, Christian
- Subjects
- *
ATEZOLIZUMAB , *ANTIGEN analysis , *THERAPEUTIC use of monoclonal antibodies , *ALGORITHMS , *CLINICAL pathology , *PATHOLOGISTS , *STAINS & staining (Microscopy) , *PATIENT selection , *TISSUE arrays , *EQUIPMENT & supplies , *DIAGNOSIS ,BLADDER tumors - Abstract
Abstract Background Recently, the Food and Drug Administration (FDA)/European Medicines Agency (EMA) restricted first-line use of atezolizumab and pembrolizumab in patients with metastasised urothelial carcinoma by defining distinct programmed cell death ligand-1 cut-offs. We analysed the diagnostic performance of all FDA/EMA-approved programmed cell death ligand-1 assays with emphasis on new restrictions for first-line treatment with atezolizumab and pembrolizumab. Patients and methods Two hundred fifty-one urothelial carcinomas were analysed on tissue microarrays with four cores of each tumour. Stains were performed in certified laboratories on Ventana Benchmark Ultra and Dako Link 48 autostainers. Stains were read on an assay-by-assay basis by two trained pathologists. Overall percentage agreement (OPA) was calculated across the preset cut-offs. Positive percentage agreement (PPA) and negative percentage agreement (NPA) were calculated across different scoring algorithms. Venn diagrams were constructed to illustrate discordance according to the recent FDA/EMA guidelines. Results The Dako 28-8, 22c3 and the Ventana SP263 assays showed high interassay correlation (r-range 0.83–0.91). Interassay correlation between the Ventana SP142 and the three other assays was moderate (r-range 0.66–0.75). OPA of 93.3% was achieved between the Dako 28-8, 22c3 and Ventana SP263 assays. OPA including the SP142 was 84.1%. Pooled PPA and NPA of different scoring algorithms was 89.4% and 95.3% for the Dako 28-8, 22c3 and the SP263 assays, respectively. With the SP142 assay, pooled PPA was 59.1%. The SP142 assay identifies fewer eligible patients for first-line treatment with atezolizumab/pembrolizumab. Conclusion Dako 28-8, 22c3 and SP263 assays show interchangeable performance. The SP142 assay shows divergent staining results. Interassay variability leads to different detection rates of eligible patients for first-line treatment with atezolizumab and pembrolizumab. Highlights • Comprehensive analysis of diagnostic performance of programmed cell death ligand-1 assays in urothelial carcinoma. • Three of the four Food and Drug Administration/EMA-approved assays are widely interchangeable. • Ventana SP142 shows divergent staining behaviour with clinical implications. • Interassay variability could lead to a withhold of first-line immune therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany.
- Author
-
Wenzel, Mike, Borkowetz, Angelika, Lieb, Verena, Hoffmann, Manuela A., Borgmann, Hendrik, Höfner, Thomas, Dotzauer, Robert, Neuberger, Manuel, Worst, Thomas S., von Hardenberg, Jost, Linxweiler, Johannes, and Klümper, Niklas
- Subjects
- *
CASTRATION-resistant prostate cancer , *CABAZITAXEL , *DOCETAXEL ,MORTALITY risk factors - Abstract
Objective: Since multiple oncological treatment options in metastatic castration-resistant prostate cancer (mCRPC) are available, optimal sequencing of therapies are under investigation. However, the efficacy of Cabazitaxel (CAB) in fourth and later lines of therapy is rarely investigated.Material and Methods: Fifty three patients with mCRPC treated with CAB in fourth line or later were included in our retrospective study, which involved eight uro-oncology centers in Germany. Clinical and tumor characteristics, as well as PSA-response rates were analyzed. Kaplan-Meier plots addressed overall survival (OS) and progression-free survival (PFS). Logistic regression models predicted risk factors of overall mortality (OM).Results: Of 53 patients, 79% (n=42), 19% (n=10) and 2% (n=1) received CAB in fourth, fifth and sixth line. A median of 4 cycles of CAB were administered. Median PSA at start of CAB was 199ng/ml (interquartile range (IQR) 70-869). In total, 89% had bone and 40% visceral metastases prior to the start of CAB. Moreover, 30% of patients received Docetaxel in first line therapy for mCRPC. Most frequent sequence of therapy was abiraterone followed by docetaxel and followed by enzalutamide. Overall, median PSA-response rate was -20% (IQR -80 to +10%). Patients with docetaxel in first line had a significantly better median PSA-response on CAB (-80 vs. 20%, P=0.03). Median OS, radiographic PFS and overall PFS were 14.8 (Confidence interval (CI): 11.0-20.8), 3.0 (CI: 2.9-4.0) and 2.9 (CI: 2.0-3.3) months, respectively. In multivariable analyses, visceral metastases, PSA >100ng/ml, ISUP4+5 and later administration of Docetaxel were predictors of OM.Conclusion: Real-world experiences indicate that favorable oncologic outcomes can be achieved with CAB especially regarding PSA-response and OS even in the fourth line or later in patients with mCRPC. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.